Blood monitoring for cancer drugs using a finger prick
Part of Cancer clinical trials.
This study tests an easier way to measure the amount of cancer medicine in your blood using a simple finger prick instead of a standard blood draw. If you are taking one of the listed oral or IV cancer drugs, you may be able to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are currently taking one of the listed cancer medicines (like Cabozantinib, Pazopanib, Sunitinib, Lenvatinib, Imatinib, Abiraterone, Enzalutamide, Nivolumab, Ipilimumab, Pembrolizumab, Atezolizumab, Bevacizumab, or Enfortumab vedotin).
- You are willing and able to give your permission to take part in the study.
- You can collect a small blood sample from your own finger using a finger prick (a tiny prick on your fingertip).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores blood and protein samples from people with cancer to help future research. You may be asked to return for follow-up appointments so the researchers can link your samples to health outcomes.
This study tests whether cancer patients can do their own blood counts at home using a finger-prick test. It will help see if home monitoring is a good option for people receiving chemotherapy.
This study tests a finger-prick blood test you can do at home to check levels of your breast cancer medication (ribociclib, abemaciclib, or palbociclib). The goal is to make monitoring easier and more convenient.
This study measures “circulating tumor markers,” meaning substances from cancer that can show up in blood, to better understand how cancer is doing after treatment. You may join if you recently received cancer care at a participating center and meet basic study and follow-up requirements.
This study looks at a non-invasive blood test to detect cancer-related “signal patterns” and see how well they match different types of cancer. It may help researchers learn better ways to find or understand cancer using less invasive testing.
This study checks how accurate a finger-prick blood test is for people getting cancer treatment. It may help reduce the need for blood draws from a vein.
Hear when a new Drug Monitoring trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.